The National Hospitals-Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire.
Br J Clin Pharmacol. 1976 Aug;3(4):621-5. doi: 10.1111/j.1365-2125.1976.tb04885.x.
The antiepileptic activity of oral frusemide (120 mg daily) was compared with that of an identical placebo in a double-blind crossover trial in fourteen patients with severe focal epilepsy who were receiving long-term therapy with established antiepileptic drugs. A statistically significant reduction in the frequency of focal fits was seen with the active drug. Marked drowsiness occurred in three patients during frusemide therapy, causing their withdrawal from the trial. A slight, but significant, rise in serum phenobarbitone concentrations was observed during frusemide therapy, but no change was seen in serum primidone or phenytoin concentrations. Frusemide significantly lowered plasma sodium and potassium concentrations, and increased plasma bicarbonate.
在 14 例接受长期标准抗癫痫药物治疗的严重局灶性癫痫患者中,进行了一项双盲交叉试验,比较了口服呋塞米(每日 120mg)的抗癫痫活性与相同安慰剂的活性。与安慰剂相比,活性药物可显著降低局灶性癫痫发作的频率。在呋塞米治疗期间,有 3 名患者出现明显嗜睡,导致他们退出试验。在呋塞米治疗期间,观察到血清苯巴比妥浓度略有但显著升高,但血清苯妥英或扑米酮浓度没有变化。呋塞米显著降低了血浆钠和钾浓度,并增加了血浆碳酸氢盐。